X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa Sells 74,773 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR traded up $0.01 during trading hours on Monday, reaching $0.49. The stock had a trading volume of 2,333,226 shares, compared to its average volume of 2,696,270. The firm has a 50-day moving average of $0.55 and a 200-day moving average of $0.61. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a market cap of $83.84 million, a price-to-earnings ratio of -5.46 and a beta of 0.14.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the third quarter valued at about $30,000. SG Americas Securities LLC bought a new position in X4 Pharmaceuticals in the 3rd quarter worth about $37,000. XTX Topco Ltd bought a new position in shares of X4 Pharmaceuticals in the second quarter worth $65,000. Rhumbline Advisers increased its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company's stock valued at $109,000 after acquiring an additional 23,831 shares during the period. Finally, Jane Street Group LLC lifted its stake in X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company's stock valued at $166,000 after purchasing an additional 126,296 shares during the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on XFOR shares. Stifel Nicolaus reduced their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research report on Tuesday, January 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.